Market Research Logo

Conference Documentation: ADC Summit 2015

Conference Documentation: ADC Summit 2015

Recent clinical successes have generated intense interest in ADC therapeutics. To develop ADCs that are more specific, more stable, and more effective; continued optimisation of the antibody, linker and payload of an ADC is critical. This conference goes to the heart of the technological challenges and asks: What does it take to develop superior ADCs and gain the clinical edge? Join us as we share, confer and debate how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
9:10
Biomarkers: Improving drug development success by linking ADC therapy to the right patient
Angela Romanelli, Senior Director, Biomarkers, ImmunoGen, Inc.
9:50
Designing novel warheads for targeted therapies: efficient strategies for making natural tubulysins, analogs, and their conjugates
Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.
10:30
Morning Coffee
11:00
RG7787, a Mesothelin-binding Pseudomonas exotoxin-based cytolytic fusion protein
Klaus Bosslet, Head Discovery Oncology, Pharma Research & Early Development , Roche Innovation Center Penzberg
11:40
Arming disease-targeting ligands with cytokines and with cytotoxic drugs
Giulio Casi, Head of Targeted Cytotoxics Development, Philochem AG
12:20
Networking Lunch
13:20
High affinity bicyclic peptides: Application to payloads in oncology
Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Limited
14:00
The Nanobody® platform: opportunity for next generation drug conjugates
Carlo Boutton, Director of Technology, Ablynx
14:40
Seriously? Folic acid can replace an antibody for targeting potent warheads to tumours?
Christopher P Leamon, Vice President of Research, Endocyte, Inc.
15:20
Afternoon Tea
15:50
Understanding the effect of target biology on the activation and metabolism of ADC
Erica Hong, Scientist Biochemistry, ImmunoGen, Inc.
16:20
Round Table Discussion: A matter of size: Is the future small?
Peter Bach, Director, BioPharmaLogic Ltd.
17:00
Can You Handle Highly Potent Compounds Safely? Are You Sure?
Justin Mason-Home, Managing Director, SafeBridge Europe, Limited
17:40
Using IP to benefit from ADC technologies
James Legg, Patent Attorney , Boult Wade Tennant
18:20
Chairman’s Closing Remarks and Close of Day One
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
David Thurston, Professor of Drug Discovery, King's College London
9:10
The onward march of ADCs – How near the end are we?
David Thurston, Professor of Drug Discovery, King's College London
9:50
Small is beautiful – antibody-targeted nanomedicines
Chris Scott, Chair of Pharmaceutical Biosciences, Queens University Belfast
10:30
Morning Coffee
11:00
Opti-linked antibody fragments as ADCs
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
11:40
From modified peptides to modified proteins: new approaches to immunological recognition
Michael Webb, Associate Professor, University of Leeds
12:20
Networking Lunch
13:20
Development of the PBD ADC Platform
Luke Masterson, Chemistry Group Leader, Spirogen
14:00
Click chemistry-triggered activation of ADCs in vivo
Marc Robillard, CEO, Tagworks Pharmaceuticals
14:40
Robust disulfide bridging reagents enable delivery of a well-characterised and multi-functional ADC platform
Vijay Chudasama, Research Associate, University College London
15:20
Afternoon Tea
16:00
Sortase-mediated antibody conjugation (SMAC™): generation of homogeneous, site-specifically conjugated antibody drug conjugates
Roger Beerli, Vice President Research & Development, NBE-Therapeutics AG
16:40
Targeting solid cancers using antibody-drug conjugates against the novel ADC targets Tissue Factor and Axl
Esther Breij, Assistant Director, Antibody Research, Genmab B V
17:00
Clinical development of ADCs: The EU landscape, trial design and the impact of the new clinical trial regulation
Natalie Thomas, Consultant, Clinical Network Services (UK) Ltd
17:40
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report